Says demand for Cologuard, value proposition “very strong.” Feels “very good” about Device, Pharma portfolio growth rates. Says “very bullish” on CGM market. Says “constantly evaluating” portfolio for performance. Says “too early to tell” the impact from crisis in Middle East. Says as a whole, company is “well set up for the year.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott organic outlook cut, says Wolfe Research
- Abbott expects Exact Sciences acquisition to accelerate long term sales growth
- Abbott expects FX to have 1% positive impact on FY26 revenue
- Abbott reports Q1 adjusted EPS $1.15, consensus $1.15
- Abbott cuts FY26 adjusted EPS view to $5.38-$5.58 from $5.55-$5.80